ABBV vs BWAY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.
BWAY shows bullish fundamentals based on deterministic rules. Financial strength is strong (F-Score 8/9). Key strengths include strong valuation and growth metrics. Price trades at a 130.9% premium to fair value estimate ($5.31), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
ABBV vs BWAY: Head-to-Head Comparison
This page compares AbbVie Inc. (ABBV) and BrainsWay Ltd. (BWAY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.